Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (NASDAQ: AMRN) is a global pharmaceutical company focused on cardiovascular disease and the development and commercialization of icosapent ethyl, marketed as VASCEPA in the United States and other regions and as VAZKEPA in Europe. The AMRN news feed on Stock Titan brings together Amarin’s press releases and related coverage so investors can follow how the company is executing on its cardiovascular strategy.
News about Amarin frequently covers clinical and scientific developments around its REDUCE-IT cardiovascular outcomes trial and subsequent post hoc analyses, including presentations at major conferences such as the American Heart Association Scientific Sessions, the European Society of Cardiology Congress and the Canadian Cardiovascular Congress. These updates often explore cardiovascular risk reduction in high-risk subgroups, mechanistic insights into eicosapentaenoic acid, and evolving guideline and regulatory perspectives on triglyceride-lowering therapies.
Investors can also expect regular updates on Amarin’s commercial performance and operating model. Recent releases have discussed the transition to a fully partnered international commercialization strategy, an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA across 59 European-focused countries, restructuring efforts to reduce operating expenses, and commentary on market dynamics for therapies targeting elevated triglycerides and severe hypertriglyceridemia.
Regulatory and policy developments are another recurring theme, including Amarin’s statements on FDA labeling changes for fenofibrate products and the implications for cardiovascular risk management. Together, these categories of news provide a view into how Amarin positions VASCEPA/VAZKEPA within global cardiovascular care, how its partnerships evolve, and how scientific data may influence future prescribing patterns. Bookmark this page to monitor AMRN news on clinical data, partnerships, financial updates and regulatory developments in one place.
Amarin (NASDAQ:AMRN) reported preliminary unaudited 2025 results and operational milestones, highlighting a year-end cash balance of $303 million, positive cash flow in Q4 2025 achieved ahead of prior expectations, and a debt-free balance sheet. The company realized ~50% of an estimated $70 million OPEX savings from its 2025 restructuring and expects the full savings by June 30, 2026. FY 2025 net revenue is expected to be $212–$217 million, with Q4 revenue of $48–$53 million. Amarin completed a long-term exclusive license and supply agreement with Recordati for VAZKEPA in 59 countries and secured regulatory approvals in South Korea and Singapore.
Amarin (NASDAQ: AMRN) presented a new REDUCE-IT post hoc aspirin analysis at AHA Scientific Sessions 2025 showing that icosapent ethyl significantly reduced cardiovascular events in high-risk, statin-treated patients with elevated triglycerides.
Among 8,179 participants (6,179 on aspirin), icosapent ethyl cut the primary endpoint by 28% in aspirin users (P<0.0001), with an absolute risk reduction 5.9% and NNT 17. Total primary events were reduced by 36% (RR 0.64; 95% CI 0.56–0.74). In the secondary prevention aspirin subgroup (n=4,867) total events fell 39% (RR 0.61; 95% CI 0.53–0.70).
The analysis found consistent benefit with or without aspirin and reported a safety profile in aspirin users consistent with the overall trial population.
Amarin (NASDAQ: AMRN) will present new analyses and mechanistic studies at the American Heart Association Scientific Sessions 2025 in New Orleans, Nov 7–10, 2025.
Highlighted items include REDUCE-IT analyses of icosapent ethyl (VASCEPA/VAZKEPA) assessing cardiovascular outcomes with or without baseline aspirin use, plus mechanistic data on EPA effects on lipoprotein(a) oxidation, anti-inflammatory actions, and endothelial protection. Specific presentations are scheduled Nov 9–10, 2025, across Abstract Board, Population Science, and Basic Science zones.
Amarin (NASDAQ: AMRN) reported Q3 2025 results showing a shift toward a fully partnered international commercial model and initial margin improvement after a June 2025 global restructuring.
Key Q3 2025 metrics: Total net revenue $49.7M (+17% YoY), Product revenue $48.6M (+16% YoY) driven by U.S. product revenue $40.9M (+34% YoY). Operating loss narrowed to $11.1M (operating margin -22%) from $25.2M year-ago. Net loss was $7.7M ($0.02/share). SG&A fell 47%; restructuring charges of $9.4M were recorded. Cash and investments totaled $286.6M and the company is debt free, targeting sustainable positive free cash flow in 2026.
Amarin (NASDAQ:AMRN) praised the FDA for updating fenofibrate labeling on Oct 27, 2025, to state a lack of cardiovascular benefit and to add safety language and a narrowed indication.
The label cites two large diabetes trials and PROMINENT, and warns of increased rhabdomyolysis risk when fibrates are combined with statins. The release notes >11 million US fibrate prescriptions in 2023, >60% co-prescribed with statins, and ~2 million fibrate patients in Western Europe.
Amarin said the change should shift prescribing toward FDA-approved, outcome-proven therapies such as VASCEPA (icosapent ethyl).
Amarin (NASDAQ: AMRN) will report third quarter 2025 financial results and host a conference call on Wednesday, October 29, 2025.
The company will release results in pre-market hours followed by a live call with senior management at 8:00 a.m. ET. Investors can join via telephone (US: 877-545-0523; International: 973-528-0016; Access Code: 459510) or via webcast on the Investor Relations website at www.amarincorp.com. A replay will be available by phone (US: 877-481-4010; International: 919-882-2331; Access Code: 53008) and online through the Investor Relations site beginning shortly after the call and available until March 29, 2026.
Amarin (NASDAQ: AMRN) and Canadian partner HLS Therapeutics will present new REDUCE-IT and EPA mechanistic data at the Canadian Cardiovascular Congress in Quebec City, Oct 23–26, 2025.
Multiple abstracts and posters—including ENCORE analyses of Icosapent Ethyl (IPE) clinical value, Lp(a) oxidation inhibition by EPA, EPA+GLP-1 receptor agonist endothelial effects, and hospitalization/death outcomes from REDUCE‑IT—are scheduled for Oct 24, 2025 (board/poster sessions at 5:30pm ET and an oral presentation at 6:00pm ET).
VASCEPA is commercialized in Canada via the HLS collaboration.
Amarin Corporation (NASDAQ:AMRN) presented new in vitro data at the European Society of Cardiology (ESC) Congress 2025 in Madrid, highlighting key mechanistic insights into VASCEPA®/VAZKEPA® (eicosapentaenoic acid/EPA).
The research revealed two significant findings: First, EPA demonstrated potential to reduce inflammation in atherosclerotic cardiovascular disease (ASCVD) by modulating the ATP-P2X7 axis and NLRP3 inflammasome activation in monocyte-derived macrophages. Second, EPA showed ability to inhibit lipoprotein(a) [Lp(a)] oxidation and attenuate its effects on oxidative stress and pro-inflammatory protein expression in endothelial cells.
These findings suggest that EPA's cardiovascular benefits may extend beyond its known triglyceride-lowering effects, potentially offering additional mechanisms for reducing cardiovascular risk in at-risk patients.
Amarin Corporation (NASDAQ:AMRN) presented three significant sub-analyses from the REDUCE-IT® trial at ESC Congress 2025, demonstrating the effectiveness of VASCEPA®/VAZKEPA® (icosapent ethyl) in reducing cardiovascular risks. Key findings showed that the treatment resulted in 9% fewer total hospitalizations and significant cardiovascular risk reductions across multiple patient subgroups.
The analyses revealed a 44% relative risk reduction in cardiovascular events for patients with CKM syndrome and eGFR <60. The treatment showed significant reductions in major adverse cardiovascular events across all quartiles of baseline ApoB and TRL-C concentrations. Additionally, the 2025 ESC/EAS Dyslipidemia Guideline Update reaffirmed icosapent ethyl as a Class IIA recommended therapy for high-risk or very high-risk patients.
Amarin Corporation (NASDAQ:AMRN) announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain, featuring new analyses from the REDUCE-IT trial and EPA mechanistic data. The presentations will focus on icosapent ethyl's (IPE) cardioprotective effects through multiple mechanisms.
The data will explore IPE's impact on inflammation, lipoprotein oxidation, cardiovascular risk associated with CV-kidney-metabolic (CKM) syndrome, and hospitalization risks. Key presentations include analyses of cardiovascular risk reduction across specific patient subtypes and mechanistic studies investigating EPA's effects on inflammasome activation and lipoprotein(a) oxidation.
The congress will feature both oral and moderated poster presentations, scheduled from August 29th to September 1st, 2025, demonstrating Amarin's commitment to advancing cardiovascular care science.